2026-06-05 FDA Warning Letter: Mineral BioSciences, LLC Cited for Unapproved New Drugs/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Unapproved New Drugs/Misbranded
TL;DR
Key takeaway: FDA issued a Warning Letter (CMS #724745) to Mineral BioSciences, LLC on June 5, 2026, following an inspection of its Goodyear, Arizona facility (November 12-24, 2025), identifying unapproved new drug violations and misbranding of Totala Fulvic Ionic Mineral Complex and Ionicell products. The agency determined these products are drugs—not dietary supplements—based on claims made on the company's websites and social media (Facebook, Instagram) that the products treat or prevent diabetes and control blood sugar levels, yet the products lack FDA approval and adequate directions for safe use by laypersons. The letter also cited Current Good Manufacturing Practice violations in the facility that render the dietary supplement versions adulterated.
Argus analysis
# FDA Warning Letter Analysis: Mineral BioSciences, LLC
**Company and Violations**
Mineral BioSciences, LLC, based in Goodyear, Arizona, received a warning letter from the FDA's Human Foods Program on June 5, 2026, following a facility inspection conducted November 12–24, 2025. The FDA identified unapproved new drug claims, misbranding violations, and manufacturing deficiencies related to two products: Totala Fulvic Ionic Mineral Complex and Ionicell. The agency reviewed the company's websites and social media pages (Facebook and Instagram) and determined that marketing claims—including statements about blood sugar control, cellular repair, blood pressure reduction, and joint pain relief—positioned these products as drugs rather than dietary supplements.
**Regulatory Citations and Implications**
The warning letter cites violations under 21 CFR Part 111 (dietary supplement manufacturing standards) and the Federal Food, Drug, and Cosmetic Act. Specifically, the products lack FDA approval as new drugs under sections 201(g)(1)(B) and 201(p), violate misbranding requirements under section 502(f)(1), and fail CGMP (Current Good Manufacturing Practice) standards. Deficiencies included inadequate facility sanitation, documented pest activity in storage areas, unsigned component specifications, and incomplete batch production records lacking equipment cleaning logs and personnel initials for component handling.
**Expected Timeline and Monitoring**
Companies typically have 15 business days to respond to warning letters. Mineral BioSciences had already submitted multiple responses (December 2025, April and May 2026), though the FDA noted inadequate documentation. Competitors and industry observers should monitor whether the company reformulates products as supplements, removes disease claims, or pursues drug approval pathways. The warning letter signals likely follow-up inspection to verify corrective actions on sanitation and documentation.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Mineral BioSciences, LLC MARCS-CMS 724745 — June 05, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Product: Drugs Recipient: Recipient Name Mr. Luke C. Blotsky Recipient Title CEO Mineral BioSciences, LLC 4050 S Sarival Ave Goodyear , AZ 85338-3233 United States Issuing Office: Human Foods Program United States June 5, 2026 WARNING LETTER CMS #724745 Dear Mr. Blotsky: The U.S. Food and Drug Administration (FDA) conducted an inspection of your facility located at 4050 S Sarival Ave, Goodyear, AZ, on November 12-24, 2025. Based on inspectional findings and subsequent review of your websites https://mineralbiosciences.com/ and https://protectcells.com/, and your Facebook and Instagram social media pages at https://www.facebook.com/ProtectCells/ and https://www.instagram.com/p/BYR6AmlDlx4/, we have identified significant violations of the Federal Food, Drug, and Cosmetic Act (the Act) and applicable regulations. You can find the Act and FDA regulations through links on FDA's home page at www.fda.gov. At the conclusion of the inspection on November 24, 2025, our investigator provided you with a Form FDA 483, Inspectional Observations (FDA 483). We acknowledge receipt of your responses dated December 18, 2025, April 13, 2026, April 30, 2026, and May 1, 2026, and we address your responses below. Unapproved New Drugs FDA reviewed your websites at the Internet addresses https://mineralbiosciences.com/ and https://protectcells.com/ in May 2026 and determined that you take orders on the website https://protectcells.com/ for your products Totala Fulvic Ionic Mineral Complex and Ionicell. We also reviewed your social media pages on Facebook (https://www.facebook.com/ProtectCells/) and Instagram (https://www.instagram.com/p/BYR6AmlDlx4/) in March 2026, where you direct consumers to your website, https://protectcells.com/, to purchase your products. Claims on your social media webpages establish that your Totala Fulvic Ionic Mineral Complex and Ionicell products are drugs under section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)] because they are intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the Act. Examples of some of the claims that provide evidence that your products are intended for use as drugs include: Totala Fulvic Ionic Mineral Complex AND Ionicell “Did you know Higher A1C levels are linked to diabetes complications? But did you also know that case reports have shown that Ioniplex can help control post-prandial blood sugar levels?” Note: Ioniplex is an ingredient in both the Totala and Ionicell products. (https://www.facebook.com/ProtectCells/, from a post dated February 24, 2022) Totala Fulvic Ionic Mineral Complex AND Ionicell “Ioniplex has been clinically shown to repair and stimulate the body at the cellular…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- When did FDA issue the warning letter to Mineral BioSciences, LLC?
- FDA issued the letter (MARCS-CMS 724745) on 2026-06-05 and posted it publicly on fda.gov on 2026-07-21.
- Is the FDA warning letter to Mineral BioSciences, LLC publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/mineral-biosciences-llc-724745-06052026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
- What is the regulatory background for a Unapproved drug warning letter?
- Unapproved-drug letters cite 21 USC 355 (NDA requirement) or 21 USC 331(d) (introduction into interstate commerce). FDA increasingly applies these provisions to homeopathic products, kratom, and certain compounded preparations.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). 2026-06-05 FDA Warning Letter: Mineral BioSciences, LLC Cited for Unapproved New Drugs/Misbranded. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-mineral-biosciences-llc-2026-06-05-unapproved-drug
"2026-06-05 FDA Warning Letter: Mineral BioSciences, LLC Cited for Unapproved New Drugs/Misbranded." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-mineral-biosciences-llc-2026-06-05-unapproved-drug.
Argus HQ Research. "2026-06-05 FDA Warning Letter: Mineral BioSciences, LLC Cited for Unapproved New Drugs/Misbranded." Digital Empire Holdings LLC. Accessed July 24, 2026. https://argushq.ai/fda/warning-letter/fda-wl-mineral-biosciences-llc-2026-06-05-unapproved-drug.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_mineral_biosciences_llc_2026_06_05_unapproved_drug_2026,
title = {2026-06-05 FDA Warning Letter: Mineral BioSciences, LLC Cited for Unapproved New Drugs/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-mineral-biosciences-llc-2026-06-05-unapproved-drug},
note = {Accessed: July 24, 2026}
}